Use of Atosiban in in Vitro Fertilization (IVF) Treatment

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

The hypothesis of this randomized double blind study is that the live birth rates are significantly higher after the use of atosiban prior to the embryo transfer in patients undergoing in vitro fertilization (IVF) treatment. This study aims to compare the live birth rates of IVF treatment between patients receiving atosiban and placebo prior to the transfer.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Hong Kong
• Collaborators: Nanfang Hospital of Southern Medical University; Vietnam National University
• Treatments: Atosiban; Vasotocin

Criteria

Inclusion Criteria:

• Age < 43 years

• Normal uterine cavity shown on ultrasound scanning

Exclusion Criteria:

• Age >=43

• Three previous IVF cycles

• Use of donor oocytes

• Natural IVF or IVM cycles

• Abnormal uterine cavity on ultrasound scanning

• ET canceled because of absent fertilization or risk of ovarian hyperstimulation syndrome

• Blastocyst transfer

• Undergoing preimplantation genetic diagnosis

• Recruited in the same study before